Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 11/20 | 0.94 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.94 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.94 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.94 |
| ▸ | HTR1A | P08908 | 3/20 | 0.94 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.94 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.94 |
| ▸ | DRD2 | P14416 | 1/20 | 0.94 |
| ▸ | DRD1 | P21728 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 1/20 | 0.94 |
| ▸ | DRD3 | P35462 | 1/20 | 0.94 |
| ▸ | SCN1A | P35498 | 1/20 | 0.94 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.94 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenidol SCHEMBL34469 | 0.97 | CHRM3 (1.00) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| Diphenidol SCHEMBL195192 | 0.95 | CHRM3 (1.00) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| SCHEMBL10307554 | 0.95 | CHRM3 (0.97) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| Pridinol SCHEMBL143298 | 0.87 | CHRM2 (1.00) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| SCHEMBL7436541 | 0.85 | CHRM3 (0.78) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| Pridinol SCHEMBL363996 | 0.85 | CHRM2 (0.97) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| Pridinol SCHEMBL29250415 | 0.85 | CHRM2 (0.97) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| Pridinol SCHEMBL27496509 | 0.85 | CHRM2 (0.97) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| SCHEMBL8967625 | 0.81 | CHRM2 (0.72) | CHRM3CHRM4CHRM2CHRM1CHRM5 | |
| SCHEMBL10307563 | 0.81 | CHRM4 (0.70) | CHRM3CHRM4CHRM2CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | CHRM1 1604/4885CHRM3 1038/4885CHRM4 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.